Literature DB >> 36099552

The correlation of the neutrophil-lymphocyte ratio to clinical and imaging parameters in patients with thyroid eye disease.

Xiaowen Zhang1, Chen Han1,2, Hongwei Wang3, Xinghong Sun4, Xin Dou5, Xueying He5, Di Wu6, Shanmei Shen1, Dalong Zhu1, Xinlin Zhang7, Yan Bi1.   

Abstract

Thyroid eye disease (TED) is the major extrathyroidal manifestation of Graves' disease (GD). Treatment choice is based on clinical activity and severity of TED, as evaluated with clinical activity score (CAS) and magnetic resonance (MR) imaging. We aimed to determine the relationship between neutrophil-to-lymphocyte ratio (NLR), a readily available indicator of systemic inflammation, and clinical and MR imaging parameters in TED patients. Eighty-seven consecutive TED patients were included. The average signal intensity ratio (SIR), average extraocular muscle (EOM) diameter, and proptosis of the study eye were extracted from MR images. A baseline NLR ≥ 2.0 was recorded in 37 (42.5%) patients and NLR < 2.0 in 50 (57.5%) patients. TED patients with NLR ≥ 2.0 were older, had a higher CAS, average SIR, average EOM diameter and proptosis, and a lower serum thyrotrophin receptor antibody level than patients with NLR < 2.0 (all P < 0.05). All MR parameters showed significant correlation with CAS (P < 0.05). NLR correlated significantly with CAS (P = 0.001), average SIR (P = 0.004), average EOM diameter (P = 0.007), and proptosis (P = 0.007). Multiple regression revealed a significant correlation between NLR and CAS (P = 0.001), average SIR (P = 0.029), and proptosis (P = 0.037). Cox regression analysis showed that a high NLR at baseline was associated with a worse clinical outcome of TED (hazard ratio 3.7, 95% CI 1.22-11.2, P = 0.02), at a median follow-up of 25 months. In conclusion, NLR was correlated with CAS and MR imaging parameters and was associated with a worse clinical outcome of TED at follow-up in patients with TED. Additional prospective studies are needed to validate our findings.

Entities:  

Keywords:  Graves’ disease; clinical activity; magnetic resonance imaging; neutrophil–lymphocyte ratio; thyroid eye disease

Year:  2022        PMID: 36099552      PMCID: PMC9578078          DOI: 10.1530/EC-22-0260

Source DB:  PubMed          Journal:  Endocr Connect        ISSN: 2049-3614            Impact factor:   3.221


  23 in total

1.  Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.

Authors:  Imam Subekti; Asman Boedisantoso; Nila Djuwita Moeloek; Sarwono Waspadji; Muchtaruddin Mansyur
Journal:  Acta Med Indones       Date:  2012-04

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  Imaging Investigation of Thyroid Eye Disease.

Authors:  Loizos C Siakallis; Jimmy M Uddin; Katherine A Miszkiel
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2018 Jul/Aug       Impact factor: 1.746

5.  Neutrophil-to-lymphocyte ratio in thyroid ophthalmopathy.

Authors:  T Celik
Journal:  Bratisl Lek Listy       Date:  2017       Impact factor: 1.278

6.  High neutrophil-to-lymphocyte ratio is associated with relapse in Graves' disease after antithyroid drug therapy.

Authors:  Mijin Kim; Bo Hyun Kim; Min Hee Jang; Jeong Mi Kim; Eun Heui Kim; Yun Kyung Jeon; Sang Soo Kim; In Joo Kim
Journal:  Endocrine       Date:  2019-11-20       Impact factor: 3.633

7.  Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Authors:  Raymond S Douglas; George J Kahaly; Amy Patel; Saba Sile; Elizabeth H Z Thompson; Renee Perdok; James C Fleming; Brian T Fowler; Claudio Marcocci; Michele Marinò; Alessandro Antonelli; Roger Dailey; Gerald J Harris; Anja Eckstein; Jade Schiffman; Rosa Tang; Christine Nelson; Mario Salvi; Sara Wester; Jeffrey W Sherman; Thomas Vescio; Robert J Holt; Terry J Smith
Journal:  N Engl J Med       Date:  2020-01-23       Impact factor: 91.245

8.  Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors:  Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

9.  Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.

Authors:  Yuji Hiromatsu; Hiroyuki Eguchi; Yuko Matsuo; Tamotsu Kato; Junichi Tani; Shiho Watanabe; Yasuo Teshima; Naohiro Araki
Journal:  Endocr J       Date:  2019-12-10       Impact factor: 2.349

10.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.